Dermatology ·
TREATgermany Registry Identifies 4% Dupilumab Poor Responders in Atopic Dermatitis
A registry analysis of 476 patients with atopic dermatitis treated with dupilumab in German dermatology practices found that 4% met the study’s definition of poor response during follow-up. Male sex, smoking, arterial hypertension and higher body mass index were more common among poor responders, but the findings require confirmation.
- Four percent met the registry’s poor-response definition.
- Stable response was recorded in 44% of patients.
- Poor responders more often had several baseline characteristics.
- The potential risk factors need confirmation.
Researchers analyzed data from the TREATgermany registry for 476 patients with atopic dermatitis who received dupilumab between June 2016 and December 2024. The observational study assessed Eczema Area and Severity Index (EASI) changes at follow-up visits, defining poor response as an EASI reduction of 40% or less at the first visit, 8–20 weeks after treatment start, and at a subsequent visit within 52 weeks.
Nineteen patients (4%) met the poor-response definition. By comparison, 209 (44%) were classified as stable responders, with an EASI reduction of at least 75% at both follow-up visits. Poor responders were significantly more often male and more frequently had smoking history, arterial hypertension and higher body mass index.
The findings describe response patterns in routine dermatological care, but the poor-responder group was small. The reported characteristics are potential risk factors, not established predictors, and the authors call for further research to confirm them. The registry analysis does not establish that these factors cause reduced response or support changing treatment on their own.
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Acta Dermato-Venereologica: Dupilumab in Atopic Dermatitis – Rate of Poor Responders and Potential Risk Factors from the TREATgermany Registry ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.